ClinicalTrials.gg
CompletedNCT02300142Updated Oct 16, 2017

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

A Phase 2 interventional study of GEN-003 Vaccine (30μg of each antigen) and GEN-003 Vaccine (60μg of each antigen) in Genital Herpes Simplex Type 2, sponsored by Genocea Biosciences, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-10-16.

Sponsored by Genocea Biosciences, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Herpes Simplex with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Herpes Simplex · United States.

Enrollment
38th of 66
37 · median 60
Started
2015
with 4 others
Phase 2
14 of 95
1 open now
Registered
68th of 95
by date
Lead sponsor
6 of 95
Genocea Biosciences, Inc.

Among the 95 studies in Herpes Simplex with a site in United States, this one is the 38th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2015, is one of 14 in phase 2, and was the 68th registered.

Herpes Simplex

166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.

Browse Herpes Simplex studies →

Open to participants now

5 of the 95 studies in Herpes Simplex with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Herpes Simplex studies recruiting now, 4 (40%) set no upper age limit and 1 (10%) stops at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Herpes Simplex with a site in United States, or all of them as a file.
02

Study summary

This is a voluntary study to allow subjects who received placebo while on GEN-003-002 to be randomized, in a blinded manner, to 1 of 6 active combinations of GEN-003 and Matrix-M2.

Objectives:

  • To compare the impact on clinical Herpes Simplex Virus type-2 (HSV-2) disease among 6 different combinations of GEN-003 antigens and Matrix-M2 adjuvant measured by:

    • Time to first clinical and/or virologic recurrence after Dose 3 (Day 43)
    • Proportion of subjects who are recurrence free at 6 and 12 months after the last dose of vaccine
    • Lesion rate (percent of days with genital lesions present) during the post-vaccination follow-up period
    • Antiviral use.
  • To evaluate the safety and tolerability of GEN-003 in combination with Matrix-M2.
03

Conditions studied

  • Genital Herpes Simplex Type 2

Browse trials for

Keywords

  • HSV
  • Herpes
  • genital infection
  • vaccine
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who received placebo in GEN-003-002 and completed the study through Day 71 per protocol, including the collection of at least 45 anogenital swabs during Days 43 to 71.
  2. Enrolled into this trial within 56 days of completing Day 71 of GEN-003-002.
  3. Willing and able to provide written .
  4. Willing to perform and comply with all study procedures including attending clinic visits as scheduled.
  5. Men and women of , must be willing to practice a highly effective method of that may include, but is not limited to, abstinence, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device (IUD), or barrier method (e.g., condom, diaphragm) for 28 days before and 90 days after receiving Study Drug.

Exclusion criteria

Exclusion Criteria:

  1. On suppressive antiviral medication within 7 days prior to the first dose of Study Drug.
  2. Collection of less than 45 anogenital swabs during Days 43 to 71 of the GEN-003-002 study.
  3. History of any form of ocular Herpes Simplex Virus (HSV) infection, HSV-related erythema multiforme, or herpes meningitis or encephalitis.
  4. individuals, including those receiving immunosuppressive doses of (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months prior to the first dose of Study Drug, any dose of corticosteroids within 30 days of the first dose of Study Drug, or high dose inhaled corticosteroids [> 960 μg/day of beclomethasone dipropionate or equivalent]) or other immunosuppressive agents.
  5. Presence or history of disease, regardless of current treatment.
  6. Positive serologic test for (HIV-1) or infection (in the absence of a negative PCR result); positive surface antigen (HBsAg) within 6 months prior to the first dose of Study Drug.
  7. laboratory abnormality or a value ≥ Grade 2 within 56 days prior to the first dose of Study Drug.
  8. Receipt of blood products within 90 days prior to the first dose of Study Drug.
  9. Receipt of a within 28 days prior to or a subunit vaccine within 14 days prior to the first dose of Study Drug or planned vaccination within 30 days following the last dose of Study Drug.
  10. Pregnant or nursing women.
  11. History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the patient's ability to comply with the requirements of the study.
  12. Other active, uncontrolled co-morbidities that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.

NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be enrolled if there have been no changes to their medication within 60 days prior to the first dose of Study Drug.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    GEN-003 Vaccine 30μg / Matrix-M 25μg

    GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (30μg of each antigen) · Biological: Matrix-M2 Adjuvant (25μg)

  • Experimental
    GEN-003 Vaccine 30μg / Matrix-M2 50μg

    GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (30μg of each antigen) · Biological: Matrix-M2 Adjuvant (50μg)

  • Experimental
    GEN-003 Vaccine 30μg / Matrix-M2 75μg

    GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (30μg of each antigen) · Biological: Matrix-M2 Adjuvant (75μg)

  • Experimental
    GEN-003 Vaccine 60μg / Matrix-M2 25μg

    GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (60μg of each antigen) · Biological: Matrix-M2 Adjuvant (25μg)

  • Experimental
    GEN-003 Vaccine 60μg / Matrix-M2 50μg

    GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (60μg of each antigen) · Biological: Matrix-M2 Adjuvant (50μg)

  • Experimental
    GEN-003 Vaccine 60μg / Matrix-M2 75μg

    GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (60μg of each antigen) · Biological: Matrix-M2 Adjuvant (75μg)

Interventions

  • HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

    Also known as: HSV Vaccine

  • HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

    Also known as: HSV Vaccine

  • Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

    Also known as: MM2, Adjuvant

  • Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

    Also known as: MM2, Adjuvant

  • Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

    Also known as: MM2, Adjuvant

06

What researchers measure

Primary outcomes

  1. Impact on clinical HSV-2 disease based on time to recurrence and lesion rate

    Time frame: 53 weeks

Secondary outcomes

  1. Number of patients with adverse events as a measure of safety and tolerability

    Time frame: 57 weeks

07

Study locations

16 sites
  • University of Alabama Vaccine Research Unit
    Birmingham, Alabama 35294-0006, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • University of Illinois Department of Medicine
    Chicago, Illinois 60612, United States
  • Indiana University Infectious Disease Research
    Indianapolis, Indiana 46202, United States
  • The Fenway Institute
    Boston, Massachusetts 02215, United States
  • UNC Global HIV Prevention and Treatment Clinical Trials Unit
    Chapel Hill, North Carolina 27599, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Westover Heights Clinic
    Portland, Oregon 97210, United States
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Tekton Research
    Austin, Texas 98745, United States
  • Center for Clinical Studies - Houston
    Houston, Texas 77030, United States
  • Center for Clinical Studies
    Houston, Texas 77065, United States
  • Center for Clinical Studies - Clear Lake/Webster
    Webster, Texas 77598, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • UW Virology Research Clinic
    Seattle, Washington 98104, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2014
First posted
Nov 24, 2014
Start
Jan 2015
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Results delay requested
Sep 11, 2017
Last update
Oct 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02300142
Lead sponsor
Genocea Biosciences, Inc.
Responsible party
Sponsor
First posted
Nov 24, 2014
Start date
Jan 2015
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Oct 16, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GEN-003 · Adjuvant

Start the discussion